A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
Clinical trial NCT04035226 · COMPLETED
Trial details
- NCT number
- NCT04035226
- Sponsor
- Janssen-Cilag Ltd.
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2019-08-02
- Primary completion
- 2022-10-27
- Enrollment
- 254
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.